(Q33870245)

29 July 2017

1 reference

title

Pathogenesis, diagnosis and management of hepatitis C. (English)

1 reference

29 July 2017

Boyer N

1

1 reference

PubMed ID

10728798

29 July 2017

Marcellin P

series ordinal

2

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

Journal of Hepatology

1 reference

29 July 2017

32

1 reference

29 July 2017

1 Suppl

1 reference

29 July 2017

98-112

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C: the clinical spectrum of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Binding of hepatitis C virus to CD81

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hypervariable regions in the putative glycoprotein of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Long-term outcome of hepatitis C infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Predictors of patient and graft survival following liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C and HIV infection: biological, clinical, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Diagnostic tests for hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus and blood transfusion: past and present risks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Improvement of hepatitis C virus RNA polymerase chain reaction through a multicentre quality control study. French Study Group for the Standardization of Hepatitis C Virus PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Immunohistochemical detection of hepatitis C antigen by monoclonal antibody TORDJI-22 compared with PCR viral detection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Clinical significance of hepatitis C virus genotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Non-isotopic detection of hepatitis C virus quasispecies by single strand conformation polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus infection: quality of life and side effects of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Treatment of chronic hepatitis C: comparative virologic response rates among the different interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Treatment of naive patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Therapy of hepatitis C: re-treatment with alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Re-treatment with interferon alfa of patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

New treatment strategies in non-responder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Therapy of hepatitis C: patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Therapy of hepatitis C: patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Treatment of acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Interferon-alpha therapy for chronic hepatitis C in special patient populations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus infection in special groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Treatment of chronic hepatitis C in special groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Early predictors of response to treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Structure of the hepatitis C virus RNA helicase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Ribozyme gene therapy for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Perspectives for a vaccine against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

Vaccination of chimpanzees against infection by the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980419-5

7 January 2021

10.1016/S0168-8278(00)80419-5

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10728798